Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sacituzumab Tirumotecan”

84 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 84 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07521670
What this trial is testing

Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)

Who this might be right for
Recurrent Adenoid Cystic CarcinomaAdenoid Cystic Carcinoma MetastaticPapillary Thyroid Carcinoma
National Cancer Centre, Singapore 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07438600
What this trial is testing

Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital 38
Testing effectiveness (Phase 2)Looking for participantsNCT07329322
What this trial is testing

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07815197
What this trial is testing

Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer

Who this might be right for
Penile Squamous Cell CarcinomaMetastatic Penile Squamous Cell Carcinoma
Latin American Cooperative Oncology Group 37
Testing effectiveness (Phase 2)Looking for participantsNCT07105852
What this trial is testing

Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma
Sir Run Run Shaw Hospital 59
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07720258
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy

Who this might be right for
Advanced Small Bowel Adenocarcinoma
National Cancer Center, Japan 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07511023
What this trial is testing

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

Who this might be right for
Phase 2Sacituzumab TirumotecanRefractory Metastatic+2 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT07371208
What this trial is testing

Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07729033
What this trial is testing

A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.

Who this might be right for
Advanced Biliary Tract Cancers
Tianjin Medical University Cancer Institute and Hospital 28
Early research (Phase 1)Active Not RecruitingNCT06049212
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Who this might be right for
Non-small Cell Lung CancerSolid TumorsProgrammed Cell Death-1 (PD1, PD-1)+2 more
Merck Sharp & Dohme LLC 30
Testing effectiveness (Phase 2)Looking for participantsNCT07548060
What this trial is testing

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital 25
Large-scale testing (Phase 3)Looking for participantsNCT06312176
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07501169
What this trial is testing

Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Who this might be right for
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sichuan University 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07314619
What this trial is testing

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer (PROC)
The First Affiliated Hospital of Zhengzhou University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07128693
What this trial is testing

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07388875
What this trial is testing

Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC

Who this might be right for
Extensive-Stage Small Cell Lung Cancer
China Medical University, China 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT07829783
What this trial is testing

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)

Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 400
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701122
What this trial is testing

Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer

Who this might be right for
Advanced Biliary Tract Cancer(BTC)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716917
What this trial is testing

Genitourinary Tumors With Sacituzumab Tirumotecan

Who this might be right for
Papillary Renal CarcinomaVariant Histology Urothelial Carcinoma
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Next Page